Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accumulated Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Accumulated Expenses for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 39.87% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 39.87% year-over-year, with the annual reading at $4.6 million for FY2025, 39.87% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $4.6 million at Century Therapeutics, down from $11.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $11.7 million in Q2 2025, with the low at $117000.0 in Q4 2022.
  • Average Accumulated Expenses over 4 years is $5.9 million, with a median of $5.9 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 8574.36% in 2023, then tumbled 56.09% in 2024.
  • Over 4 years, Accumulated Expenses stood at $117000.0 in 2022, then surged by 8574.36% to $10.1 million in 2023, then fell by 24.1% to $7.7 million in 2024, then crashed by 39.87% to $4.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.6 million, $11.1 million, and $11.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.